A Phase 1,Open Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Dalbavancin in Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment for Bacterial Infections

Project: Research project

Project Details

StatusFinished
Effective start/end date11/13/13 → 11/12/15

Funding

  • DUKE UNIVERSITY: $21,625.00